Researchers have developed a DNA-based treatment aimed at PCSK9, a protein closely tied to high LDL cholesterol and atherosclerosis. The approach is designed to reduce the protein's production rather than rely on statins, which are the current standard for lowering cholesterol.
In laboratory tests on human liver cells, the most effective molecule reduced PCSK9 protein by 87%. When tested in genetically modified mice, the same treatment lowered cholesterol by 47%, according to the study reported by ScienceDaily.
The results are early, and the treatment has not been tested in humans. Still, the findings suggest that DNA-based therapies could one day offer an alternative or complement to statins for managing high cholesterol.